PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

01 Aug 2024 06:45:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

31 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate at BTIG Virtual Biotechnology Conference

29 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

12 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

15 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

09 May 2024 16:46:46 By Nasdaq GlobeNewswire

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Details of Virtual KOL Event

03 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

27 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

20 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

22 Jan 2024 15:45:19 By Nasdaq GlobeNewswire

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

16 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 Dec 2023 15:50:00 By Nasdaq GlobeNewswire

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

28 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

14 Nov 2023 06:30:55 By Nasdaq GlobeNewswire

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

09 Nov 2023 07:00:01 By Nasdaq GlobeNewswire